Evercore ISI Group maintains Medline at Outperform, raises price target to $44 from $38

Evercore ISI Group kept its Outperform rating on Medline and increased its price target to $44 from $38, suggesting a 9.0% upside from the Nov 4 close of $40.35. Recent analyst price targets for Medline range from $43 to $55.

Original reporting
Published Nov 5, 2026, 2:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evercore ISI Group maintains Medline at Outperform, raises price target to $44 from $38 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade suggests modest upside potential but lacks concrete earnings data.

02

Market read

A modest analyst upgrade that may attract short‑term buying interest.

03

What to watch

No disclosed earnings or guidance; the upgrade is based on qualitative assessment.

Relevance 6/10Novelty 6/10Timing: today

Background

Evercore ISI upgraded Medline to Outperform and lifted the price target from $38 to $44.

Market effects

Analyst target raise may lift peer valuation in the medical supplies sector.

Limited to U.S. investors tracking Medline and related healthcare stocks.

Minimal global impact; primarily a U.S. equity micro‑cap note.

Counterpoint

The target raise could be premature if Medline's earnings miss expectations.

Key entities

  • Medline

    Medical supplies distributor, private (no US ticker).

  • Evercore ISI Group

    Equity research firm issuing the rating change.

Related articles

$MDLNMed

Medline stock falls as shareholders price secondary offering

Medline Inc (MDLN) shares fell 3.5% premarket after selling stockholders, including affiliates of Blackstone and Carlyle, priced a 60M share secondary offering at $35.50 per share. Medline will repurchase $200M of stock from these sellers. The offering is expected to close November 23, 2026, with underwriters having a 30-day option for additional shares. Medline is not selling shares and will not receive proceeds.

$MDLNHighAI 9/10

Why is Medline stock sliding today?

Medline (MDLN) stock fell 3.3% in pre-market trading after a consortium of shareholders priced a secondary offering of 60 million shares at $35.50 each, totaling $2.13 billion. The offering's below-market price and a securities fraud investigation by Bleichmar Fonti & Auld LLP contributed to the decline. Medline is not selling shares and will not receive proceeds. The stock has dropped significantly from its 52-week high of $50.88.